

(SANTE)

From: [REDACTED] (CAB-KYRIAKIDES) on behalf of KYRIAKIDES Stella (CAB-KYRIAKIDES)
Sent: mardi 28 avril 2020 12:41
To: CAB KYRIAKIDES ARCHIVES; ROSSIDES Giorgos (CAB-KYRIAKIDES); OJALA Annukka (CAB-KYRIAKIDES)
Subject: FW: Letter from Spanish Minister of Health
Attachments: Carta 1899-2020 Mrs. Stella Kyriakides.pdf
Follow Up Flag: Follow up
Flag Status: Completed

From: secmin@mscbs.es
Sent: Tuesday, April 28, 2020 12:11 PM
To: KYRIAKIDES Stella (CAB-KYRIAKIDES)
Subject: Letter from Spanish Minister of Health

Good morning,
By order of the Spanish Minister of Health, , we are pleased to sending you attached a copy of a letter addressed to Mrs. Stella Kyriakides.
If you have any questions, please let us know.

Kind regards,

Secretaría del Ministro de Sanidad
Ministerio de Sanidad

Paseo del Prado 18-20
28071 Madrid
Teléfono: 91 596 10 00
secmin@msssi.es



CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.

CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the

use of the addresser. If you are not the addresser, we ask you to notify to the sender, do not pass its content and delete the original.



Stella Kyriakides
Member of the European Commission
Health and Food Safety

Madrid, April 27, 2020

Dear Commissioner Kyriakides:

Thank you for the letter that conveys the recommendations of the European Commission, the EMA and the experts group on clinical trials to facilitate the development of clinical research in the EU.

We consider that clinical research is a fundamental aspect in the development of treatments to improve the lives of our citizens. In this sense, and from the beginning of the crisis that has hit our country hard, we began to work with sponsors, researchers, healthcare centres and patients to implement measures that would minimize the impact of this health crisis in the clinical trials that are being carried out in our country. Our recommendations are completely aligned with those that the Commission has promoted, and the Spanish Agency for Medicines and Medical Devices has planned an update of the documents already published on its website.

We believe that preserving this important activity requires the necessary flexibility to minimize the impact on clinical research while continuing to guarantee the rights of the people who participate in them and the validity of the results.

We are fully committed to this task and we greatly appreciate the interest and guidance of the Commission in this regard.

Yours sincerely,

Salvador Illa Roca